Showing 6011-6020 of 8816 results for "".
- Finacea Foam 15% Approved for Treatment of Inflammatory Papules and Pustules in Patients with Mild to Moderate Rosaceahttps://practicaldermatology.com/news/finacea-foam-15-approved-for-treatment-of-inflammatory-papules-and-pustules-in-patients-with-mild-to-moderate-rosacea/2458899/The FDA approved Finacea® (azelaic acid) Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The approval is based on results from two pivotal clinical trials examining the efficacy and safety of Finacea® Foam com
- Almirall Completes Investment in Suneva Medicalhttps://practicaldermatology.com/news/almirall-completes-investment-in-suneva-medical/2458900/Barcelona-based Almirall, a global pharmaceutical company, has closed a $15 million in Series C equity investment in Suneva Medical, Inc., marketer of Bellafill®. This product i
- ASDS Skin Cancer Program Honoredhttps://practicaldermatology.com/news/asds-skin-cancer-program-honored/2458901/A skin cancer screening program offered by the American Society for Dermatologic Surgery has been commended with a national 2015 Power of A award for “helping to make the world a better place.” The Choose Skin Health program has been named a Power of A Gold Award winner by the
- FDA Approves Odomzo for Locally Advanced BCChttps://practicaldermatology.com/news/fda-approves-odomzo-sonidegib-for-locally-advanced-bcc/2458903/The FDA approved Novartis’ Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radi
- ASDS Finds Age Affects Facial Treatment Preferenceshttps://practicaldermatology.com/news/asds-finds-age-affects-facial-treatment-preferences/2458908/A research-based analysis published in Dermatologic Surgery found that facial treatment preferences among women often are tied to their age. Younger women are more likely to seek cosmetic medical treatments for the upper face while women 50 and older prioritize treatments of the lower fa
- Galderma Receives FDA Approval for Epiduo Forte for Acnehttps://practicaldermatology.com/news/galderma-receives-fda-approval-for-epiduo-forte-for-acne/2458909/The FDA approved Galderma’s antibiotic-free Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5%, for the once-daily, topical treatment of acne vulgaris. Epiduo Forte Gel is the first combination of these strengths of the retinoid, adapalene, and benzoyl peroxide, developed for
- Research: Slow-release Nitric Oxide Particles May Reduce Inflammatory Acnehttps://practicaldermatology.com/news/research-slow-release-nitric-oxide-particles-may-reduce-inflammatory-acne/2458910/GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology. This research, published in the Journal of Investigative Dermatology, identified that the nanoparticles were eff
- Brickell Biotech Appoints Patricia Walker, MD, PhD as President and CSOhttps://practicaldermatology.com/news/brickell-biotech-appoints-patricia-walker-md-phd-as-president-and-cso/2458912/Patricia Walker, MD, PhD has joined Brickell Biotech, Inc. as President and Chief Scientific Officer. Dr. Walker, a board-certified dermatologist specializing in medical and aesthetic dermatology, most recently served as the Chief Medical Officer for Kythera Biopharmaceuticals, Inc. Over
- CMS and AMA Announce Efforts to Ease ICD-10 Transitionhttps://practicaldermatology.com/news/cms-and-ama-announce-efforts-to-ease-icd-10-transition/2458913/The Centers for Medicare & Medicaid Services (CMS) and the American Medical Association (AMA) are initiating efforts to continue to help physicians get ready ahead of the October 1 deadline to move from ICD-9 to ICD-10 coding for medical diagnoses and inpatient hospital procedures. In respons
- Cynosure's SculpSure Receives Expanded FDA Clearance for Lipolysis of the Abdomenhttps://practicaldermatology.com/news/cynosures-sculpsure-receives-expanded-fda-clearance-for-lipolysis-of-the-abdomen/2458914/Cynosure, Inc. has received 510(k) clearance from the FDA to market SculpSure™ for non-invasive lipolysis of the abdomen. In May, the FDA cleared SculpSure for non-invasive lipolysis of the flanks. SculpSure is a safe, clinically proven treatment designed to reduce fat non-invasivel